AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
fluphenazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1212 | 69-23-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A phenothiazine used in the treatment of PSYCHOSES. Its properties and uses are generally similar to those of CHLORPROMAZINE.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | O |
| 1 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.03 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.65 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 2.70 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 2.90 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 9.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.04 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 12.30 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.782 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.132 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 28.184 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 38.194 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 1.780 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 4.880 | % | High | 1 |
| herg | hERG pIC50 | 5.994 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 38.019 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 66.222 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 1.630 | % | High | 1 |
| kinase-safety-class | ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP3K7,MAPK10,MAPK7,MET,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,TEK,TGFBR1 | 31 | |||
| kinase-selectivity-class | AXL,EPHB4,PDK4 | 3 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 3.556 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 126.765 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 2.280 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 9.638 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 1 | |||
| pppb | Pig plasma protein binding (% unbound) | 5.050 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 227.510 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 11.250 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 1.730 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 33.343 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 9, 1959 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neuroleptic malignant syndrome | 88.47 | 37.62 | 23 | 1082 | 15073 | 90612269 |
| Akathisia | 60.53 | 37.62 | 16 | 1089 | 11143 | 90616199 |
| Extrapyramidal disorder | 54.52 | 37.62 | 16 | 1089 | 16287 | 90611055 |
| Salivary hypersecretion | 53.94 | 37.62 | 14 | 1091 | 9078 | 90618264 |
| Accommodation disorder | 50.98 | 37.62 | 8 | 1097 | 406 | 90626936 |
| Blood prolactin increased | 49.75 | 37.62 | 11 | 1094 | 3626 | 90623716 |
| Suicide attempt | 45.81 | 37.62 | 21 | 1084 | 75378 | 90551964 |
| Intentional overdose | 38.53 | 37.62 | 20 | 1085 | 93814 | 90533528 |
| Torsade de pointes | 38.31 | 37.62 | 12 | 1093 | 15170 | 90612172 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Priapism | 146.92 | 39.54 | 35 | 1277 | 6372 | 42613651 |
| Neuroleptic malignant syndrome | 125.37 | 39.54 | 40 | 1272 | 21432 | 42598591 |
| Sedation | 123.10 | 39.54 | 43 | 1269 | 30432 | 42589591 |
| Compartment syndrome | 60.16 | 39.54 | 15 | 1297 | 3274 | 42616749 |
| Salivary hypersecretion | 58.09 | 39.54 | 19 | 1293 | 10924 | 42609099 |
| Torsade de pointes | 54.14 | 39.54 | 17 | 1295 | 8577 | 42611446 |
| Parkinsonism | 46.67 | 39.54 | 16 | 1296 | 10607 | 42609416 |
| Completed suicide | 42.64 | 39.54 | 30 | 1282 | 96435 | 42523588 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neuroleptic malignant syndrome | 221.25 | 40.69 | 63 | 2239 | 33996 | 110553001 |
| Priapism | 146.57 | 40.69 | 32 | 2270 | 5829 | 110581168 |
| Salivary hypersecretion | 120.99 | 40.69 | 34 | 2268 | 17387 | 110569610 |
| Torsade de pointes | 87.05 | 40.69 | 28 | 2274 | 22572 | 110564425 |
| Extrapyramidal disorder | 84.20 | 40.69 | 29 | 2273 | 28838 | 110558159 |
| Sedation | 74.93 | 40.69 | 34 | 2268 | 69649 | 110517348 |
| Parkinsonism | 67.46 | 40.69 | 23 | 2279 | 22164 | 110564833 |
| Akathisia | 65.06 | 40.69 | 21 | 2281 | 17092 | 110569905 |
| Compartment syndrome | 57.22 | 40.69 | 15 | 2287 | 5895 | 110581102 |
| Tardive dyskinesia | 44.90 | 40.69 | 15 | 2287 | 13564 | 110573433 |
| Rhabdomyolysis | 44.67 | 40.69 | 29 | 2273 | 120372 | 110466625 |
| Accommodation disorder | 43.05 | 40.69 | 8 | 2294 | 645 | 110586352 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05AB02 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperazine structure |
| FDA CS | M0016525 | Phenothiazines |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:37930 | phenothiazine antipsychotic drug |
| CHEBI has role | CHEBI:48561 | dopaminergic antagonist |
| CHEBI has role | CHEBI:149553 | anticoronaviral agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| FDA EPC | N0000175746 | Phenothiazine |
Related Drugs by ATC class:
N05AB Phenothiazines with piperazine structure 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
| Psychotic disorder | indication | 69322001 | |
| Alcoholism | contraindication | 7200002 | |
| Organophosphate poisoning | contraindication | 8260003 | |
| Weight gain finding | contraindication | 8943002 | |
| Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
| Senile dementia | contraindication | 15662003 | |
| Chronic disease of respiratory system | contraindication | 17097001 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Orthostatic hypotension | contraindication | 28651003 | |
| Torsades de pointes | contraindication | 31722008 | |
| Parkinsonism | contraindication | 32798002 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Chronic heart failure | contraindication | 48447003 | |
| Bradycardia | contraindication | 48867003 | |
| Extrapyramidal disease | contraindication | 76349003 | |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Stupor | contraindication | 89458003 | |
| Tardive dyskinesia | contraindication | 102449007 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Acute disease of cardiovascular system | contraindication | 128487001 | |
| Angina pectoris | contraindication | 194828000 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Metabolic syndrome X | contraindication | 237602007 | DOID:14221 |
| Hyperprolactinemia | contraindication | 237662005 | DOID:12700 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Coma | contraindication | 371632003 | |
| At risk for aspiration | contraindication | 371736008 | |
| Visual impairment | contraindication | 397540003 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Congenital long QT syndrome | contraindication | 442917000 | |
| Carcinoma of female breast | contraindication | 447782002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.21 | Basic |
| pKa2 | 4.21 | Basic |
| pKa3 | 2.72 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 9.27 | WOMBAT-PK | CHEMBL | |||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 7.60 | DRUG MATRIX | |||||
| Mu-type opioid receptor | GPCR | Ki | 5.08 | DRUG MATRIX | |||||
| D(1A) dopamine receptor | GPCR | Ki | 7.65 | WOMBAT-PK | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.50 | WOMBAT-PK | |||||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 8.07 | DRUG MATRIX | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | Ki | 5.33 | DRUG MATRIX | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 6.10 | DRUG MATRIX | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.71 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.84 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 8.04 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 7.46 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 7.46 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 7 | GPCR | Ki | 8.10 | WOMBAT-PK | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 8.19 | WOMBAT-PK | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 7.09 | WOMBAT-PK | |||||
| D(3) dopamine receptor | GPCR | Ki | 9.37 | WOMBAT-PK | |||||
| D(1B) dopamine receptor | GPCR | Ki | 7.89 | WOMBAT-PK | |||||
| Histamine H1 receptor | GPCR | Ki | 7.79 | WOMBAT-PK | |||||
| Histamine H2 receptor | GPCR | Ki | 6.25 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.58 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 6.00 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.32 | DRUG MATRIX | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 6.45 | WOMBAT-PK | |||||
| Beta-3 adrenergic receptor | GPCR | Ki | 4.66 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 6.48 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | Ki | 6.48 | WOMBAT-PK | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 7.54 | WOMBAT-PK | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.79 | DRUG MATRIX | |||||
| Adenosine receptor A3 | GPCR | Ki | 5.17 | DRUG MATRIX | |||||
| D(4) dopamine receptor | GPCR | Ki | 7.54 | WOMBAT-PK | |||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 8.02 | DRUG MATRIX | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 7.89 | WOMBAT-PK | |||||
| Kappa-type opioid receptor | GPCR | Ki | 5.01 | DRUG MATRIX | |||||
| Delta-type opioid receptor | GPCR | Ki | 5.07 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 5A | GPCR | Ki | 6.84 | WOMBAT-PK | |||||
| 5-hydroxytryptamine receptor 1E | GPCR | Ki | 6.27 | WOMBAT-PK | |||||
| Epidermal growth factor receptor | Kinase | IC50 | 4.40 | DRUG MATRIX | |||||
| Potassium channel subfamily K member 2 | Ion channel | IC50 | 5.33 | CHEMBL | |||||
| Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.10 | DRUG MATRIX | |||||
| Receptor tyrosine-protein kinase erbB-2 | Kinase | IC50 | 4.71 | DRUG MATRIX | |||||
| Histone deacetylase 6 | Enzyme | IC50 | 5.25 | CHEMBL | |||||
| Substance-K receptor | GPCR | Ki | 5.13 | DRUG MATRIX | |||||
| Melanocortin receptor 5 | GPCR | Ki | 5.05 | DRUG MATRIX | |||||
| Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 5.43 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | IC50 | 5.78 | CHEMBL | |||||
| Androgen receptor | Transcription factor | Ki | 6.10 | CHEMBL | |||||
| Trypanothione reductase | Enzyme | Ki | 4.67 | CHEMBL | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 7.72 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 6.06 | DRUG MATRIX | |||||
| Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 7.01 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 8.10 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 6 | GPCR | ANTAGONIST | Ki | 7.80 | IUPHAR | ||||
| Pleiotropic ABC efflux transporter of multiple drugs | Transporter | IC50 | 5.77 | CHEMBL | |||||
| Adenylate cyclase | Enzyme | IC50 | 7.10 | CHEMBL | |||||
| Alpha-1A adrenergic receptor | GPCR | IC50 | 7.62 | CHEMBL | |||||
| Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | Enzyme | IC50 | 4.82 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019762 | VUID |
| N0000147853 | NUI |
| D00791 | KEGG_DRUG |
| 146-56-5 | SECONDARY_CAS_RN |
| 4017723 | VANDF |
| 4019762 | VANDF |
| C0016368 | UMLSCUI |
| CHEBI:5123 | CHEBI |
| CHEMBL726 | ChEMBL_ID |
| CHEMBL1448187 | ChEMBL_ID |
| D005476 | MESH_DESCRIPTOR_UI |
| DB00623 | DRUGBANK_ID |
| 204 | IUPHAR_LIGAND_ID |
| 946 | INN_ID |
| S79426A41Z | UNII |
| 3372 | PUBCHEM_CID |
| 203207 | RXNORM |
| 4348 | MMSL |
| 4750 | MMSL |
| d00237 | MMSL |
| 001473 | NDDF |
| 001476 | NDDF |
| 372730004 | SNOMEDCT_US |
| 41365009 | SNOMEDCT_US |
| 61678008 | SNOMEDCT_US |
| S79426A41Z | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0653 | SOLUTION, CONCENTRATE | 5 mg | ORAL | ANDA | 16 sections |
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0654 | ELIXIR | 0.50 mg | ORAL | ANDA | 16 sections |
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1788 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 14 sections |
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1789 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 14 sections |
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1790 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 14 sections |
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1791 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 14 sections |
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-6003 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 16 sections |
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-6004 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 16 sections |
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-6005 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 16 sections |
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-6006 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 16 sections |
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7157 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 14 sections |
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7158 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 14 sections |
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7159 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 14 sections |
| Fluphenazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7160 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 14 sections |
| FLUPHENAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-725 | TABLET | 1 mg | ORAL | ANDA | 14 sections |
| FLUPHENAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-725 | TABLET | 1 mg | ORAL | ANDA | 14 sections |
| FLUPHENAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-726 | TABLET | 2.50 mg | ORAL | ANDA | 14 sections |
| FLUPHENAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-726 | TABLET | 2.50 mg | ORAL | ANDA | 14 sections |
| FLUPHENAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-727 | TABLET | 5 mg | ORAL | ANDA | 14 sections |
| FLUPHENAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-727 | TABLET | 5 mg | ORAL | ANDA | 14 sections |
| FLUPHENAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-728 | TABLET | 10 mg | ORAL | ANDA | 14 sections |
| FLUPHENAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-728 | TABLET | 10 mg | ORAL | ANDA | 14 sections |
| Fluphenazine Hydrochoride | Human Prescription Drug Label | 1 | 16571-889 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 13 sections |
| Fluphenazine Hydrochoride | Human Prescription Drug Label | 1 | 16571-889 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 13 sections |
| Fluphenazine Hydrochoride | Human Prescription Drug Label | 1 | 16571-890 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 13 sections |
| Fluphenazine Hydrochoride | Human Prescription Drug Label | 1 | 16571-890 | TABLET, FILM COATED | 2.50 mg | ORAL | ANDA | 13 sections |
| Fluphenazine Hydrochoride | Human Prescription Drug Label | 1 | 16571-891 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 13 sections |
| Fluphenazine Hydrochoride | Human Prescription Drug Label | 1 | 16571-891 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 13 sections |
| Fluphenazine Hydrochoride | Human Prescription Drug Label | 1 | 16571-892 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 13 sections |
| Fluphenazine Hydrochoride | Human Prescription Drug Label | 1 | 16571-892 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 13 sections |